ArticleBlood advances2023
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML.
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.British journal of haematology · 2026Article
- Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.International journal of hematology · 2026Review
- Successful treatment of relapsed FLT3-mutated donor cell-derived MDS/AML with FLT3 inhibitor gilteritinib.Annals of hematology · 2026Article
- Post-transplantation gilteritinib maintenance therapy and therapeutic drug monitoring in pediatric acute myeloid leukemia with FLT3-internal tandem duplication.Cancer chemotherapy and pharmacology · 2026Article
- Three-year follow-up of low-dose, early-start gilteritinib maintenance in posttransplant patients with R/RBlood neoplasia · 2025Article
- Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.International journal of hematology · 2025Article
- FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML.Annals of hematology · 2024Article
- Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.International journal of molecular sciences · 2024Review
- Post-stem cell transplant maintenance in FLT3EJHaem · 2024Article
- Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.